## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Personees)

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * Bonello William						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner				
		ansaction (N	Ionth	/Day/Year)			X_ Officer (give title below) Other (specify below) Chief Financial Officer			
4	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
Date	Execution Date, if	(Instr. 8)		(A) or Disposed of (D)			Owned Following Reported Transaction(s)	Ownership of Indir Form: Benefic	Beneficial	
		Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
03/01/2022		A		-	A	\$ 0	102,742	D		
03/01/2022		F		397 <sup>(2)</sup>	D	\$ 0	102,345	D		
03/02/2022		F	•	620 (3)	D	\$ 0	101,725	D		
	(Middle)  (Zip)  2. Transaction Date (Month/Day/Year)  03/01/2022  03/01/2022	NEOGENOMIC  (Middle)  3. Date of Earliest Tr 03/01/2022  4. If Amendment, Da  (Zip)  2. Transaction Date (Month/Day/Year)  2A. Deemed Execution Date, if any (Month/Day/Year)  03/01/2022  03/01/2022	NEOGENOMICS INC [NE   1   1   1   1   1   1   1   1   1	NEOGENOMICS INC [NEO]	3. Date of Earliest Transaction (Month/Day/Year)   03/01/2022   4. If Amendment, Date Original Filed(Month/Day/Year)   2A. Deemed   Execution Date (Month/Day/Year)   3. Transaction   Code (Instr. 8)   (Instr. 3, 4	NEOGENOMICS INC [NEO]	NEOGENOMICS INC [NEO]	NEOGENOMICS INC [NEO]   Director   Director   NEOGENOMICS INC [NEO]   NEOGENOMICS INC [NEO]	NEOGENOMICS INC [NEO]   10% Owner   10%	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Security	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	tion	of Derivative		(Month/Day	ate			Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form of Derivative Security: Direct (D) or Indirect (I)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option (Right to Buy)	\$ 7.52							<u>(4)</u>	04/28/2022	Common Stock	10,727.00		10,727	D	
Stock Option (Right to Buy)	\$ 8.03							(5)	02/26/2023	Common Stock	45,370.00		45,370	D	
Stock Option (Right to Buy)	\$ 19.60							<u>(6)</u>	03/01/2024	Common Stock	41,167.00		41,167	D	
Stock Option (Right to Buy)	\$ 28.33							(7)	03/02/2027	Common Stock	37,514.00		37,514	D	
Stock Option (Right to Buy)	\$ 53.17							(8)	03/02/2028	Common Stock	24,619.00		24,619	D	
Stock Option (Right to Buy)	\$ 21.41	03/01/2022		A		99,772		<u>(9)</u>	03/01/2029	Common Stock	99,772.00	\$ 0	99,772	D	

#### **Reporting Owners**

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Bonello William 9490 NEOGENOMICS WAY FORT MYERS, FL 33912			Chief Financial Officer					

#### **Signatures**

/s/ Halley E. Gilbert, Attorney-in-Fact	03/03/2022
**Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On March 1, 2022, Mr. Bonello was granted 40,869 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant
- (2) Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2022 vesting of restricted stock.
- (3) Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2022 vesting of restricted stock.
- (4) On April 28, 2017, Mr. Bonello was granted 100,000 stock options. These options vested ratably over the first three anniversary dates of the grant date.
- (5) On February 26, 2018, Mr. Bonello was granted 120,500 stock options. These options vested ratably over the first three anniversary dates of the grant date.
- (6) On March 1, 2019, Mr. Bonello was granted 41,167 stock options. These options vest ratably over the first four anniversary dates of the grant date.
- (7) On March 2, 2020, Mr. Bonello was granted 37,514 stock options. These options vest ratably over the first four anniversary dates of the grant date.
- (8) On March 2, 2021, Mr. Bonello was granted 24,619 stock options. These options vest ratably over the first four anniversary dates of the grant date.
- (9) On March 1, 2022, Mr. Bonello was granted 99,772 stock options. These options vest ratably over the first four anniversary dates of the grant date.

#### Remarks:

Exhibit List:

Exhibit 24 - Limited Power Of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Exhibit 24

LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints William Bonello, Halley Gilbert, and Ali Olivo, and each of them individually, with full power of substitution, as the undersigned's true and lawfu (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and (2) execute for and on behalf of the undersigned, in the undersigned's capacity as officer and/or director of NeoGenomics, Inc. (the "Company"), Forms 3, 4, 5 and any Schedules 13D or 13G in acco (3) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4, or 5 or Schedule 13D or 13G, complete and e (4) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of each such attorney-in-fact, may be of benefit to, in the best interest of, or legally req The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exe This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D or 13G with respect to the undersigned's hold IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 20th day of January, 2022.

/s/ Bill Bonell